Midazolam sedation for percutaneous liver biopsy.
Control of patient respiration is needed to safely perform percutaneous liver biopsy (PLB) and may be adversely affected by sedation. The purpose of this study was to evaluate the safety of PLB with intravenous midazolam and to evaluate patient acceptance of PLB with and without sedation. Two hundred seventeen consecutive patients underwent 301 percutaneous liver biopsies. One hundred fifty-one of the biopsies were done after the patients were sedated with intravenous midazolam immediately before the biopsy. The last 61 patients were questioned after the biopsy to evaluate the discomfort of the procedure, their memory of the procedure, and their willingness to undergo another PLB. The major complication rate was similar in the midazolam-treated (0.7%) and untreated (0.7%) groups. The midazolam-treated patients had a numerically lower mean pain score (1.5 +/- 0.4 vs 4.0 +/- 0.7) (mean +/- SEM) (P = 0.07) and significantly lower mean memory score (4.8 +/- 0.7 vs 9.9 +/- 0.1) (P < 0.01) than the untreated patients. The treated and untreated groups had similar mean willingness for repeat PLB scores (9.3 +/- 0.3 vs 9.1 +/- 0.6). We conclude that: (1) there is no increased risk of PLB with midazolam and (2) patients have less memory of the procedure with midazolam.
Alexander
J A
JA
Department of Medicine, Burns Clinic Medical Center, Petoskey, Michigan 49770.
Smith
B J
BJ
D000771:Anesthesia, Intravenous; D001707:Biopsy, Needle / Q000009:adverse effects; D003258:Consumer Behavior; D006801:Humans; D008099:Liver / Q000473:pathology*; D008568:Memory / Q000187:drug effects; D008874:Midazolam; D010146:Pain / Q000209:etiology; D011292:Premedication; D012307:Risk Factors
D008874:Midazolam